Fig. 2From: Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT)Proportion of patients with CES-D score ≥ 16 over time according to treatment group. Figure caption: Proportion of patients with an increased CES-D score (≥ 16) at each assessment, by treatment group. *From week 24 onwards, all patients received infliximab. CES-D, Center for Epidemiologic Studies Depression ScaleBack to article page